Described : Actualité Described en direct - P4 | Bourse Reflex
Accueil > Tags > Described

  • Toutes les actualités en rapport avec « Described »

02/12 18:00 Described - Benedikt Timmerman resumes CEO position at Genticel

12/11 18:00 Described - Q3 REVENUES GROWTH: +188% - EXECUTIVE MANAGEMENT TEAM EXPANSION IN ASIA AND USA AND ENHANCEMENT OF THE GO-TO-MARKET STRATEGY

29/10 18:00 Described - Genticel Announces First Patient Treated in U.S. Phase 1 Clinical Trial of GTL001, Company's Therapeutic Vaccine Candidate against HPV 16/18 Infections

28/10 18:45 Described - Business Update - Third Quarter 2015

28/09 19:15 Described - 1st half 2015 : Agreement signed on MPG, and significant advances in 100% bio-based L-Methionine

21/09 17:40 Described - Genticel presents first half 2015 financial results, operational progress and outlook

08/09 07:30 Described - US patent granted for use of Genticel's antigen delivery vectors in combination therapy to treat cancer

01/09 18:00 Described - GENTICEL to meet investors

10/08 18:00 Described - New EUR 18 million financing aimed at accelerating the development in connected health, particularly in the USA

28/07 18:00 Described - Business Update - Second Quarter 2015

23/07 18:05 Described - Description of the share buy-back programme approved by the AGM of 22 July 2015

22/07 08:00 Described - Strengthen financial structure to accelerate development - Maximum potential capital increase of EUR 14.6 million over 3 years upon conversion and exercise of all OCABSA and warrants

07/07 18:00 Described - Independent Data Safety Monitoring Board Recommends Continuation per Protocol of Genticel's Phase 2 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate

03/07 18:00 Described - Summary of Genticel's liquidity contract with Oddo Corporate Finance

02/07 18:15 Described - Genticel CFO, Martin Koch, Appointed CEO to Replace Benedikt Timmerman during Temporary Medical Leave of Absence

16/06 07:00 Described - Genticel Receives FDA Clearance of IND Application for U.S. Phase 1 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate

05/06 06:45 Described - The Apax France VI Fund to distribute its Albioma shares to its investors - Altamir to keep its stake in the Company

01/06 07:00 Described - Genticel annonce des résultats positifs de preuve de concept préclinique pour GTL002, le nouveau candidat vaccin thérapeutique multivalent HPV issu de Vaxiclase, sa plateforme technologique propriétaire

01/06 07:00 Described - Genticel Announces Positive Preclinical Proof of Concept Results of GTL002, its New Multivalent HPV Therapeutic Vaccine Candidate Based on Company's Versatile Vaxiclase Platform

28/04 19:00 Described - Business Update - First Quarter 2015